Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 12, 2024

SELL
$5.63 - $8.27 $741,769 - $1.09 Million
-131,753 Reduced 72.23%
50,642 $342,000
Q2 2023

Aug 11, 2023

BUY
$11.12 - $22.2 $106,029 - $211,677
9,535 Added 5.52%
182,395 $2.09 Million
Q1 2023

May 11, 2023

BUY
$18.7 - $23.07 $1.34 Million - $1.66 Million
71,764 Added 70.99%
172,860 $3.48 Million
Q4 2022

Feb 13, 2023

SELL
$18.12 - $27.32 $43,343 - $65,349
-2,392 Reduced 2.31%
101,096 $2.29 Million
Q3 2022

Nov 08, 2022

BUY
$16.98 - $25.54 $1.52 Million - $2.29 Million
89,548 Added 642.38%
103,488 $1.94 Million
Q2 2022

Aug 12, 2022

BUY
$13.15 - $20.45 $183,311 - $285,073
13,940 New
13,940 $260,000
Q3 2020

Nov 13, 2020

SELL
$35.98 - $47.66 $2.35 Million - $3.11 Million
-65,210 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$45.06 - $67.74 $254,769 - $383,001
-5,654 Reduced 7.98%
65,210 $2.94 Million
Q1 2020

May 14, 2020

BUY
$40.01 - $73.97 $201,450 - $372,438
5,035 Added 7.65%
70,864 $3.36 Million
Q4 2019

Feb 13, 2020

BUY
$37.13 - $74.62 $392,649 - $789,106
10,575 Added 19.14%
65,829 $4.72 Million
Q3 2019

Nov 13, 2019

SELL
$39.36 - $76.8 $838,131 - $1.64 Million
-21,294 Reduced 27.82%
55,254 $2.18 Million
Q2 2019

Aug 08, 2019

SELL
$52.76 - $82.19 $126,465 - $197,009
-2,397 Reduced 3.04%
76,548 $5.98 Million
Q1 2019

May 13, 2019

BUY
$27.39 - $68.41 $738,407 - $1.84 Million
26,959 Added 51.86%
78,945 $4.71 Million
Q4 2018

Feb 14, 2019

SELL
$22.8 - $33.93 $53,488 - $79,599
-2,346 Reduced 4.32%
51,986 $1.5 Million
Q3 2018

Nov 13, 2018

BUY
$29.75 - $43.08 $139,200 - $201,571
4,679 Added 9.42%
54,332 $1.98 Million
Q2 2018

Aug 13, 2018

BUY
$21.96 - $39.94 $1.09 Million - $1.98 Million
49,653 New
49,653 $1.88 Million

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $712M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Allianz Asset Management Gmb H Portfolio

Follow Allianz Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Allianz Asset Management Gmb H with notifications on news.